Capital Increase in Genmab as a Result of Employee Warrant

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement

Copenhagen, Denmark; August 17, 2016 – Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 347,825 shares as a consequence of the exercise of employee warrants.

The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:

  • 5,625 shares at DKK 31.75,
  • 61,000 shares at DKK 40.41,
  • 11,250 shares at DKK 46.74,
  • 1,000 shares at DKK 55.85,
  • 500 shares at DKK 68.65,
  • 3,250 shares at DKK 79.25,
  • 19,000 shares at DKK 80.55,
  • 125 shares at DKK 98,
  • 1,000 shares at DKK 129.75,
  • 1,500 shares at DKK 174,
  • 100 shares at DKK 215.60,
  • 3,776 shares at DKK 224,
  • 1,850 shares at DKK 225.30,
  • 14,874 shares at DKK 225.90,
  • 1,225 shares at DKK 231.50,
  • 1,000 shares at DKK 234,
  • 750 shares at DKK 234.75,
  • 4,500 shares at DKK 246,
  • 24,825 shares at DKK 254,
  • 21,750 shares at DKK 272,
  • 2,775 shares at DKK 326.50,
  • 1,500 shares at DKK 329,
  • 3,500 shares at DKK 330,
  • 8,125 shares at DKK 337.40,
  • 141,250 shares at DKK 352.50,
  • 10,012 shares at DKK 364,
  • 588 shares at DKK 466.20, and
  • 1,175 shares at DKK 623.50.

Proceeds to the company are approximately DKK 83.9 million. The increase corresponds to approx. 0.6 % of the company's share capital.

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription, i.e. inter alia full rights to dividends for the financial year 2016. The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. Genmab A/S' current share capital amounts to DKK 59,833,932 and will after the capital increase be DKK 60,181,757. The capital increase is expected to be finalized shortly. About Genmab Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and DARZALEX® (daratumumab) for the treatment of heavily pretreated or double refractory multiple myeloma. Daratumumab is in clinical development for additional multiple myeloma indications and for non-Hodgkin’s lymphoma. Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies.  The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com .   Contact:           Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com . Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab ® ; the Y-shaped Genmab logo ® ; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo ® ; the HexaBody logo™; HuMax ® ; HuMax-CD20 ® ; DuoBody ® ; HexaBody ® and UniBody ® . Arzerra ® is a trademark of Novartis AG or its affiliates. DARZALEX ® is a trademark of Janssen Biotech, Inc.

Company Announcement no. 34 CVR no. 2102 3884

Genmab A/S Bredgade 34E 1260 Copenhagen K Denmark

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 181

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Cargo Drones to Skyrocket with $9.14B Value by 2031

Updated Category News Views 0

Riding the Drone Wave I tell you what, folks, the whole business of cargo drones is getting frickin' interesting. These flying gizmos, once dismissed as science fiction, are now barging their way into logistics discussions like an uninvited guest who's too worthwhile to ignore. MarketsandMarkets™ reckons this market's about to smash through the $9 billion ceiling by...

Continue Reading
Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 34

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 207

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 297

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Dar Global Expands Jeddah Portfolio with $267M Project

Updated Category News Views 0

Dar Global's Big Jeddah Move: A $267M Bet Alright, let's dive into what Dar Global's been up to in Saudi Arabia. They've just announced a whopping SAR 1 billion development project in Jeddah, bringing an international luxury brand to the city with an exclusive co-branded residential concept. Now that's something to chew on for any investor eyeing the Middle East's real...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 86

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 129

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 292

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading

Top 5 Most Recently Viewed Articles

Carota Unveils Innovative MaaS Service to Transform Mobility

Updated Category News Views 248

Carota Announces Launch of Transformative MaaS Service In a significant move for the transportation sector, Carota has introduced its innovative MaaS (Mobility as a Service) smart mobility service. This decision comes as a response to the rapid changes in global mobility services, highlighting Carota's commitment to adapting and evolving to meet the needs of the modern...

Continue Reading
Fossil Group Sees Growth with Strong Q2 2025 Financials

Updated Category News Views 185

Fossil Group's Financial Performance in Q2 2025 Fossil Group, Inc. (NASDAQ: FOSL) has announced its financial results for the second quarter of 2025, showcasing significant progress amid a fluctuating market landscape. The company recorded worldwide net sales of $220 million, marking a year-over-year decline, yet also presenting an encouraging operating income. Sales...

Continue Reading
Exciting UPCX Global Staking Opportunity with Major Rewards

Updated Category News Views 141

UPCX Limited-Time Staking Event Unveiled UPCX, an innovative blockchain financial services platform, proudly announces an engaging staking opportunity that is designed to foster user participation and spur innovation within its ecosystem. This exciting event invites users to take part in a limited-time stakes initiative, offering a significant reward pool of 4,900 UPC,...

Continue Reading
PepGen Inc. Shareholder Alert: Lawsuit Update and Key Details

Updated Category News Views 187

Update on the PepGen Inc. Class Action Lawsuit Levi & Korsinsky, LLP has taken significant steps to notify investors in PepGen Inc. of a class action securities lawsuit aimed at protecting shareholders' interests. Investors should be aware that the lawsuit concerns allegations of securities fraud that impacted investors during a defined time frame. Understanding the Class...

Continue Reading
Synchronoss Technologies Engages Investors via Upcoming Events

Updated Category News Views 116

Synchronoss Technologies Engages Investors with Upcoming Conferences Synchronoss Technologies Inc. (“Synchronoss” or the “Company”) (Nasdaq: SNCR), a renowned leader in Personal Cloud platforms, is set to make a significant impact at two investor conferences. The company's President and CEO, Jeff Miller, along with CFO, Louis Ferraro, are ready to share insights...

Continue Reading